Pertussis Toxin
Founded in 2017, Sigma Chemical Co., Ltd. supplies over 100 countries with high-quality chemicals. We are dedicated to safety, innovation, and global cooperation.
Product Description
Pertussis toxin (PT), an ADP-ribosylating AB-type protein toxin produced by Bordetella pertussis, is essential for pertussis pathogenesis and serves as a critical component in acellular pertussis vaccine (aPV) production. Recent advances in PT research have focused on three major areas: purification methodologies, therapeutic inhibition, and immunomodulatory effects.
- Natural Source: Pertussis toxin (PTx) is a protein exotoxin produced and secreted by the Gram-negative bacterium Bordetella pertussis, the causative agent of whooping cough.
- Production for Vaccines: For use in acellular pertussis vaccines, PTx is purified from bacterial culture supernatants. Because native PTx is too toxic for direct use in vaccines, it must undergo a detoxification process.
- Detoxification Methods:
- Chemical Detoxification: This is the traditional method, using agents like glutaraldehyde or formaldehyde. Glutaraldehyde reacts with amino groups (e.g., N-terminal, lysine) and sulfhydryl groups, causing cross-linking and irreversible structural changes that reduce toxicity. The process parameters (e.g., glutaraldehyde concentration, buffer pH, incubation time) must be carefully controlled to balance toxicity reduction with the preservation of immunogenicity.
- Genetic Detoxification: This is a newer approach that involves creating genetically detoxified pertussis toxin (gPT) through specific amino acid substitutions (e.g., Arg9/Lys and Glu129/Gly). This method results in a toxin that is structurally nearly identical to the native wild-type toxin, which can trigger a more robust and long-lasting immune response (e.g., Th1/Th17 phenotype) compared to chemically detoxified PTd.
Uses and Applications
- Vaccine Component: The primary and most critical use of pertussis toxin is as a core antigen in acellular pertussis (aP) vaccines (in its detoxified form, PTd) and as a component in combination vaccines (e.g., DTaP, TdaP). It is considered an indispensable antigen for inducing protective immunity against B. pertussis.
- Monovalent Vaccine: Chemically detoxified PT has been used as a monovalent vaccine in Denmark, demonstrating protective efficacy comparable to multi-component vaccines.
- Research Tool: In its active form, PTx is a powerful research tool used to:
- Study G protein-coupled receptor (GPCR) signaling, as it ADP-ribosylates and inactivates Gi alpha subunits.
- Induce experimental autoimmune encephalomyelitis (EAE) in animal models (e.g., SJL/J mice), which is the most well-studied animal model for multiple sclerosis (MS). PTx is administered as an adjuvant to break blood-brain barrier tolerance.
- Study neuroinflammation and immune cell trafficking.
Properties and Characteristics
Structure: PTx is an AB5-type bacterial toxin with a molecular weight of approximately 106 kDa (PubChem lists ~5879 Da for the single S1 subunit sequence, but the holotoxin is ~105-106 kDa).
- A Protomer (Enzymatic domain): Consists of a single S1 subunit (26 kDa). It possesses ADP-ribosyltransferase activity, which is responsible for the toxin's intracellular effects.
- B Oligomer (Binding domain): Consists of five subunits: S2 (22 kDa), S3 (22 kDa), S4 (two copies, 12 kDa), and S5 (11 kDa). This domain binds to carbohydrate receptors (e.g., sialylated glycans) on host cell surfaces, facilitating toxin entry.
Mechanism of Action (Active Toxin):
- Binding: The B oligomer binds to cell surface receptors.
- Entry: The toxin is internalized via endocytosis and undergoes retrograde transport to the endoplasmic reticulum.
- Enzymatic Activity: The S1 subunit is translocated into the cytosol where it catalyzes the ADP-ribosylation of the Gi alpha subunits of heterotrimeric G proteins.
- Biological Effect: This ADP-ribosylation inactivates the Gi protein, leading to a sustained increase in intracellular cyclic AMP (cAMP) levels. Elevated cAMP disrupts normal cellular signaling, including chemokine synthesis and innate immune responses.
Biochemical Activities: PTx possesses several measurable biological activities, including:
- ADP-ribosyltransferase activity (catalytic function of S1).
- Carbohydrate-binding activity (binding function of the B oligomer).
- CHO cell clustering activity (cytotoxicity on Chinese hamster ovary cells).
- Histamine sensitization, leukocytosis promotion, and islet activation in animal models.
Safety and Handling
Toxicity: Native PTx is highly toxic and is a key virulence factor responsible for the systemic manifestations of whooping cough.
Clinical Symptoms of Pertussis Related to PTx: The toxin contributes to several characteristic features of the disease:
- Persistent Cough: May involve a complex interaction with bradykinin.
- Inhibition of Fever: Blocks the PGE2-EP3 pathway via ADP-ribosylation of Gi protein.
- Leukocytosis: Disrupts leukocyte migration and retention, causing an accumulation of white blood cells in the circulation. This is a major risk factor for severe and fatal pertussis in infants.
- Pulmonary Hypertension: Disrupts age-dependent GPCR signaling, a severe complication in infants.
Exposure Routes: Ingestion, inhalation, and dermal contact (e.g., in a laboratory setting).
Treatment for Exposure: Effective antibiotics (e.g., erythromycin, azithromycin, clarithromycin) shorten the infectious period but do not always alter the disease outcome if given late. Trimethoprim-sulfamethoxazole is an alternative.
Detoxification: For safe use in vaccines, PTx must be rigorously detoxified (chemically or genetically) to eliminate its toxic enzymatic and binding activities while retaining its immunogenicity. Over-detoxification can compromise vaccine efficacy.